37th week of 2010 patent applcation highlights part 51 |
Patent application number | Title | Published |
20100234277 | COADMINISTRATION OF ALPHA-FETOPROTEIN AND A DISEASE MODIFYING ANTI-RHEUMATIC DRUG FOR TREATING INFLAMMATORY ARTHRITIC DISEASE - The present invention relates to methods for treating an anti-inflammatory arthritic disease by coadministering therapeutically effective amounts of an alpha-fetoprotein (or a biologically active fragment thereof) and a disease modifying anti-rheumatic drug (DMARD) to a patient in need thereof. Also disclosed are compositions and kits that include therapeutically effective amounts of an alpha-fetoprotein (or a biologically active fragment thereof) and a DMARD. | 2010-09-16 |
20100234278 | PROPHYLACTIC AND/OR THERAPEUTIC AGENTS FOR PERIPHERAL NEUROPATHY - When a pharmaceutical composition for preventing and/or treating peripheral neuropathy caused by chromosomal microtubule inhibition, which comprises erythropoietin as an active ingredient, is administered to patients receiving a microtubule inhibitor as an anticancer agent, such treatment alleviates peripheral neuropathy in the patients and enables increased dosage, prolonged period and increased frequency for administration of the above anticancer agent, which were never before achieved. Thus, the pharmaceutical composition not only contributes to improvement of QOL in the patients, but also enables prolongation of life in the patients. | 2010-09-16 |
20100234279 | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same - The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier. | 2010-09-16 |
20100234280 | ANTISENSE ANTIBACTERIAL METHOD AND COMPOUND - An antibacterial antisense conjugate and method of using the same for treating a bacterial infection in a mammalian host are disclosed. The conjugate includes an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotide contains 10-20 nucleotide bases and has a targeting nucleic acid sequence complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a T | 2010-09-16 |
20100234281 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD - A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications. | 2010-09-16 |
20100234282 | SYSTEM FOR DELIVERING NUCLEIC ACIDS FOR SUPPRESSING TARGET GENE EXPRESSION BY UTILIZING ENDOGENOUS CHYLOMICRON - The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into chylomiclon, particularly nucleic acids to which an alpha-tocopherol is bound for suppressing a target gene expression, can be delivered more safely and efficiently into hepatic cells in vivo by administering the nucleic aids under the condition where the production of chylomicron is induced in the body. Alternatively, alpha-tocopherol-bound nucleic acids are mixed with extracted chylomiclon, and then they are administered. Consequently, a target gene expression is suppressed, thereby a disease caused by an elevated expression of the target gene can be treated more safely and efficiently. | 2010-09-16 |
20100234283 | IMMUNOGENIC EPITOPES, PEPTIDOMIMETICS, AND ANTI-PEPTIDE ANTIBODIES, AND METHODS OF THEIR USE - Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised to VEGF peptide mimics, HER-2 epitopes, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. | 2010-09-16 |
20100234284 | Pharmaceutical compositions based on NK2 antagonists for pediatric use - Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics. | 2010-09-16 |
20100234285 | Benzofuranyl Derivatives - The present invention provides compounds of Formula (I) | 2010-09-16 |
20100234286 | PRETERM FORMULA - The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance. | 2010-09-16 |
20100234288 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER - Sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compositions and method of using such compositions. The sustained release compositions are useful in providing therapeutically effective levels of active agent(s) for extended periods of time. | 2010-09-16 |
20100234289 | INTEGRIN BINDING RGD-LIPOPEPTIDES WITH GENE TRANSFER ACTIVITIES - The present invention provides synthesis of a novel series of cationic lipopeptides with integrin-binding RGD functionalities. The invention also provides high L27 (transformed S1 80, mouse sarcoma cells) cell tropic gene transfer properties of these novel RGD-lipopeptides. Since 127 cell surface contains over expressed integrins, the present class of lipopeptides with integrin-binding RGD ligands are likely to find future applications in targeting anti-cancer genes/drugs to the endothelial cells of tumor vasculatures (possessing over expressed integrins). | 2010-09-16 |
20100234290 | Stabilized Insulin-like Growth Factor Polypeptides - The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented. | 2010-09-16 |
20100234291 | PREPARATION AND USE OF LOW-BLEEDING ANTICOAGULANT FUSION PROTEIN - Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof. | 2010-09-16 |
20100234292 | METHODS OF ASSESSING A PROPENSITY OF CLINICAL OUTCOME FOR A FEMALE MAMMAL SUFFERING FROM BREAST CANCER - The present invention relates to a method of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer in view of the expression of specific nucleic acid sequences in a biological sample. | 2010-09-16 |
20100234293 | Novel Neurotrophic Factors - The invention relates to neublastinneurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 2010-09-16 |
20100234294 | IDENTIFICATION OF NEW ISOFORMS OF THE MHC-CLASS I SPECIFIC RECEPTOR CD160 AND USES THEREOF - The present invention concerns an isolated polypeptide comprising a sequence selected in the group comprising SEQ ID NO.7, its orthologs, and derivatives thereof; a polynucleotide comprising a nucleic acid sequence encoding for said polypeptide; a vector comprising said polynucleotide; a host cell genetically engineered with said polynucleotide or with said vector; a pharmaceutical composition comprising said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, and optionally a pharmaceutically acceptable carrier; a method for screening for antagonists and/or agonists of said polypeptide; and uses of said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, for the manufacture of a medicament. | 2010-09-16 |
20100234295 | Treating Alzheimer's Disease And Osteoporosis And Reducing Aging - Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity. | 2010-09-16 |
20100234296 | FOOD MATERIAL FOR INHIBITING OSTEOCLASTOGENESIS - Disclosed is an osteoclastogenesis inhibitory agent which comprises a milk protein fraction having the following properties (1) to (4) and the agent is excellent in an osteoclastogenesis inhibitory effect and useful for preventing or treating bone diseases:
| 2010-09-16 |
20100234297 | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease. | 2010-09-16 |
20100234298 | MATRIX PROTEIN COMPOSITIONS FOR INDUCTION OF APOPTOSIS - Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms. | 2010-09-16 |
20100234299 | STABLE FORMULATION OF MODIFIED GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 2010-09-16 |
20100234300 | PROAEROLYSIN CONTAINING PROTEASE ACTIVATION SEQUENCES AND METHODS OF USE FOR TREATMENT OF PROSTATE CANCER - Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed. | 2010-09-16 |
20100234301 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 2010-09-16 |
20100234302 | PEPTIDE FOR INDUCTION OF IMMUNE TOLERANCE AS TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention relates to D-amino acid peptides and their use in methods for the diagnosis and/or treatment of immune disorders such as systemic lupus erythematosus. | 2010-09-16 |
20100234303 | AGENTS, METHODS AND USES - The present invention relates to agents, compositions and methods for use in medicine. In particular, the invention relates to agents related to GnRH peptides. | 2010-09-16 |
20100234304 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure. | 2010-09-16 |
20100234305 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 2010-09-16 |
20100234306 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-09-16 |
20100234307 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain biphenyl amino acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 2010-09-16 |
20100234308 | WAKE-UP REMEDY - A wake-up remedy that for persons with the subjective symptoms of feeling languid after wake-up, having a hard time awaking, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a wake-up remedy containing alanylglutamine or its salt as an active ingredient. | 2010-09-16 |
20100234309 | Dendrimer Compositions - Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans. | 2010-09-16 |
20100234310 | ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE - Isolated compounds and combinations of isolated compounds isolated from | 2010-09-16 |
20100234311 | Methicillin-Resistant Staphylococcus Aureus Active Metabolites - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from | 2010-09-16 |
20100234312 | AVERMECTIN DERIVATIVES - Novel avermectin derivatives of the formula (I) | 2010-09-16 |
20100234313 | STABILIZED MICRONISED PARTICLES - The present invention relates to a method for preparing a suspension of micronised particles of a solid organic compound, which method comprises subjecting the solid organic compound to size reduction by wet grinding under pH conditions wherein the intrinsic surface charge of the size-reduced organic compound is sufficient to keep the suspension stable. | 2010-09-16 |
20100234314 | IDARUBICIN FOR THE TREATMENT OF LYMPHOMA IN A DOG - The present invention relates to a method of treating a lymphoma in a dog comprising administering to a dog in need of such treatment a therapeutically effective amount of idarubicin or a pharmaceutically acceptable salt thereof. | 2010-09-16 |
20100234315 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND BEHAVIORAL DISORDERS - In one aspect, the present invention provides methods that comprise administering to a patient an active agent that comprises one or more of protoveratrine A, protoveratrine B, cevadine, veratramine and veratrosine in an amount that is effective to lessen the severity or occurrence of at least one symptom indicative of the disorder. | 2010-09-16 |
20100234316 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection - The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. | 2010-09-16 |
20100234317 | USE OF DIFRUCTOSE ANHYDRIDE-CONTAINING COMPOSITION - A method for improving bowel movement of a subject desiring such an improvement, includes administering to the subject a defructose anhydride (DFA) in an amount effective to improve bowel movement. | 2010-09-16 |
20100234318 | OPHTHALMIC COMPOSITION CONTAINING ALGINIC ACID OR SALT THEREOF - An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof. | 2010-09-16 |
20100234319 | Complex of Polymeric Quaternary Ammonium and Anionic Polymers as a New Antimicrobial Agent for Ophthalmic Compositions - Disclosed herein are ophthalmic solutions and methods of using the solutions which comprise a complex of at least one cationic component and an anionic polymer, wherein the complex can be used as an antimicrobial agent. The solutions described have complexes which can be dissolved in aqueous ophthalmic solutions due to both lower charge load and lower total polymer concentrations than commonly taught. The complexes display different antimicrobial profiles than the non-complexed antimicrobial agents. | 2010-09-16 |
20100234320 | EMULSIFYING COMPOSITIONS BASED ON ALKYL POLYGLYCOSIDES AND ESTERS - Emulsifying composition containing 1 to 98% of a mixture of alkyl glycosides, a mixture of alcohol esters, a mixture of alcohol esters, 1 to 90% of an alcohol and 0 to 97% of a mixture of alkyl glycoside esters. | 2010-09-16 |
20100234321 | OILY COSMETIC AND COSMETIC PRODUCT - A composition is prepared to comprise (a) 50 to 99% by weight of an oily phase that is a liquid at 25° C., (b) 1 to 7% by weight of dextrin (palmitate/2-ethylhexanoate), and (c) 0.001 to 10% by weight of a coloring material and/or pearlescent agent other than a laminated film powder are contained, followed by making the viscosity thereof at 30° C. when measured with a BL viscometer to be 3,000 to 20,000 mPa·s. In addition, (d) silicic acid anhydride and/or hydrophobized silicic acid anhydride is added thereto. | 2010-09-16 |
20100234322 | TREATMENT OF OSTEOARTHRITIS - There is provided a therapeutic agent for treating osteoarthritis, which is a drug comprising hyaluronan as an active ingredient. The hyaluronan is preferably a tetrasaccharide including two units, with a single unit being -D-glucuronic acid-β-1,3-D-N-acetylglucosamine-β-1,4- (HA4). | 2010-09-16 |
20100234323 | Antimicrobial Acids and Salts - The invention relates to novel acidic siloxane derivatives, the use, methods of use or processes making use of siloxane derivatives of this type, especially to achieve an anti-microbial, preservative and/or antiadhesive effect, for the protection of articles and/or materials, and a process for the manufacture of the novel compounds. The siloxane acids (which may also be in salt form) have the formula (I), formula (II) and/or formula (III), wherein the symbols have the meanings given in the specification. | 2010-09-16 |
20100234324 | Quinazolinamide derivatives - Novel quinazolinamide derivatives of the formula (I), in which R | 2010-09-16 |
20100234325 | 4-Peroxycyclophosphamide use thereof - 4-Peroxycyclophosphamide is provided along with its method of preparation. The compound is useful for treating human cancer, particularly human primary and metastatic malignant brain tumors. | 2010-09-16 |
20100234326 | COMPOSITION FOR DECELERATING THE AGING IN THE ORGANISM AND FOR EXTENDING THE LIFE TIME THEREOF AND THE USE OF SAID COMPOSITION - The invention relates to pharmacology, medicine and gerontology, in particular to a class of chemical structures (1) which can be used in compositions, in the form of geroprotectors, for extending the life time, decelerating, stopping or for reversing the process of the entirety of the organism's dysfunctions causing the mammal ageing and for preventing and treating particular senile diseases. | 2010-09-16 |
20100234327 | Novel Triazene Compounds For The Treatment Of Cancer - The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects. | 2010-09-16 |
20100234328 | Antimicrobial Compositions And Related Methods - A liquid antimicrobial composition comprising an organic acid and one or more anionic surfactants is disclosed. In one embodiment, the organic acid is lactic acid and the anionic surfactant is sodium octane sulfonate. In a preferred embodiment, the antimicrobial solution is formulated as a teat dip for lactating animals, particularly cows. In other embodiments, the antimicrobial compositions may be used in personal care, hard surface care including hard surface disinfection in households, food processing, hospitals, restaurants, hotels, showers, or topically as hand soaps, surgical scrubs, and hoof disease mitigators. | 2010-09-16 |
20100234329 | INGESTIBLE FILM COMPOSITION - The present invention relates to a novel ingestible film composition. More specifically, the invention is directed to a water-based, enzymatically-digested carboxymethylcellulose (CMC-Enz) film composition that is suitable for delivering pharmaceutical drugs, vitamins, natural products and other products to humans and animals. The invention further includes a method for manufacturing the novel composition. Advantageously, the film composition can accommodate an active ingredient in a quantity of up to approximately 60% of the overall weight of the final film. | 2010-09-16 |
20100234330 | Novel Estrogenic Compounds - Novel estrogenic compounds of Formula I are provided. | 2010-09-16 |
20100234331 | HEXAHYDRO-CYCLOOCTYL PYRAZOLE CANNABINOID MODULATORS - This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): | 2010-09-16 |
20100234332 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl. 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R | 2010-09-16 |
20100234333 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - A compound according to formula (I) | 2010-09-16 |
20100234334 | NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteriods of general formula (I) and pharmaceutical acceptable salts or stereoisomers thereof wherein R is the corticosteriod residue of formulas (II): The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological disease and ocular diseases. | 2010-09-16 |
20100234335 | NEUROSTEROID COMPOUNDS - The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions related to or resulting from apoptosis, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS), retinal degeneration and detachment, peripheral neuropathy caused by genetic abnormalities, diabetes, polio, herpes, AIDS and chemotherapy, brain trauma, or ischemia and stroke. The active compounds are represented by Formula (I): wherein R | 2010-09-16 |
20100234336 | Ophthalmic Compositions - An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid. | 2010-09-16 |
20100234337 | FOAMING COMPOSITIONS FOR HAIR CARE - The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating | 2010-09-16 |
20100234338 | CHELATING AGENTS OF METAL IONS, THEIR METHODS OF PREPARATION AND THEIR APPLICATIONS - The present invention relates to compounds that can be used as metal-ion-chelating agents or as depolluting agents, corresponding to general formula (I) below: | 2010-09-16 |
20100234339 | SILVER(I) COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT,PROPHYLAXIS AND PREVENTION OF INFECTIONS - The present invention provides new Ag(I) complexes with derivatives of nicotinic acid, nicotinamide and related pyridine ligands, and pharmaceutical compositions comprising such Ag(I) complexes for use in the treatment, prophylaxis and prevention of infections. The invention further provides a solvent free method for the synthesis of Ag(I) complexes containing substituted pyridines, pyrazines and pyrimidines as ligands. | 2010-09-16 |
20100234340 | Substituted Spiroamide Compounds - Substituted spiroamide compounds corresponding to formula (I): | 2010-09-16 |
20100234341 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS - Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R | 2010-09-16 |
20100234342 | EZETIMIBE COMPOSITIONS - This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife, methods for their preparation, and methods for treatment using the same. | 2010-09-16 |
20100234343 | INHIBITORS OF ION CHANNELS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel. | 2010-09-16 |
20100234344 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS - The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims. | 2010-09-16 |
20100234345 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to isothiazolylidene containing compounds of Formula (I) | 2010-09-16 |
20100234346 | NOVEL PYRIMIDINE DERIVATIVES - The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX) | 2010-09-16 |
20100234347 | Substituted Pteridines substituted with a Four-Membered Heterocycle - The invention relates to novel pteridines of formula (1), | 2010-09-16 |
20100234348 | COMPOSITIONS AND METHODS FOR POTENTIATING ANTIBIOTIC ACTIVITY - The present invention provides compounds that potentiate the activity of antibiotic agents, particularly quinolones such as norflaxin. The invention further provides compositions, e.g., pharmaceutical compositions, comprising the inventive compounds. The invention also provides compositions comprising an antibiotic (e.g., a quinolone) and a compound that potentiates activity of the antibiotic. The invention further provides methods of treating a subject comprising administering any of the inventive compounds or compositions to the subject. The invention also provides screening methods to identify compounds that potentiate the activity of an antibiotic, e.g., a quinolone. | 2010-09-16 |
20100234349 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER - This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders. | 2010-09-16 |
20100234350 | PLATELET ADP RECEPTOR INHIBITORS - Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof. | 2010-09-16 |
20100234351 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND - A compound of the formula: | 2010-09-16 |
20100234352 | FACTOR XA INHIBITORS - The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample. | 2010-09-16 |
20100234353 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2010-09-16 |
20100234354 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 2010-09-16 |
20100234355 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES - The invention concerns a compound of formula (I) | 2010-09-16 |
20100234356 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: | 2010-09-16 |
20100234357 | Benzofuran derivatives - The present invention provides a compound represented by the following formula (I): | 2010-09-16 |
20100234358 | NERAMEXANE FOR THE TREATMENT OF NYSTAGMUS - The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate. | 2010-09-16 |
20100234359 | TREATMENT OF SLEEP DISORDERS - The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl 4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia. | 2010-09-16 |
20100234360 | Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations - The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than ½. The methods of the present invention may be used to address a whole host of undesirable mental and neurological conditions. | 2010-09-16 |
20100234361 | SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to the CGRP antagonists of general formula | 2010-09-16 |
20100234362 | USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL - The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or less. The present invention also relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising orally administering to said mammal in need thereof a daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis. | 2010-09-16 |
20100234363 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 2010-09-16 |
20100234364 | CCR2 INHIBITORS AND METHODS OF USE THEREOF - Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists. | 2010-09-16 |
20100234365 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1). | 2010-09-16 |
20100234366 | Use of Strobilurins for the Treatment of Disorders of Iron Metabolism - Strobilurin derivatives can be employed for the treatment and/or prevention of disorders of iron metabolism in mammals. | 2010-09-16 |
20100234367 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS - Provided herein are aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. | 2010-09-16 |
20100234368 | CONDENSED RING COMPOUND AND USE THEREOF - The present invention relates to a compound of formula (I) | 2010-09-16 |
20100234369 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS - Novel 5-cyanothienopyridines of the formula (I), in which R | 2010-09-16 |
20100234370 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 2010-09-16 |
20100234371 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof - The invention relates to bicyclic heterocycles of general formula (I), in which R | 2010-09-16 |
20100234372 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS - The invention relates to substituted 2-mercaptoquinoline-3-carboxamides, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments. | 2010-09-16 |
20100234373 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I | 2010-09-16 |
20100234374 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma. | 2010-09-16 |
20100234375 | HIV INHIBITING 5-(HYDROXYMETHYLENE AND AMINOMETHYLENE) SUBSTITUTED PYRIMIDINES - This invention concerns 5-(hydroxymethylene and aminomethylene)pyrimidine derivatives having HIV (Human Immunodeficiency Virus) replication inhibiting properties, to the preparation thereof and to pharmaceutical compositions comprising these compounds. | 2010-09-16 |
20100234376 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors - The invention provides a novel class of compounds of the Formula I: | 2010-09-16 |
20100234377 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE - The present invention relates to compounds of general formula (I): | 2010-09-16 |